Journal
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
Volume 232, Issue -, Pages -Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.jphotobiol.2022.112477
Keywords
PLK1; BI-2536; Volasertib; BI-6727; Ro-3280; Fluorescence spectroscopy; Molecular modeling
Categories
Funding
- Universidad de Castilla-La Mancha [2020-GRIN-29016]
- Consejeria de Economia y Conocimiento (Junta de Andalucia) [FQM-337]
- Universidad de Jaen (Accion 1)
- Diputacion de Albacete [DIPUAB-16-GARZONRUIZ]
- Universidad de Castilla-La Mancha
- Junta de Comunidades de Castilla-La Mancha [2018/15132]
Ask authors/readers for more resources
This study investigated the interactions between novel kinase inhibitors and PLK1 through fluorescence spectroscopy and molecular dynamics calculations. The findings showed stable protein-ligand complexes and higher affinity of the inhibitors for PLK1 compared to the competitive compound ATP.
In the present work, the interactions of the novel kinase inhibitors BI-2536, Volasetib (BI-6727) and Ro-3280 with the pharmacological target PLK1 have been studied by fluorescence spectroscopy and molecular dynamics calculations. High Stern-Volmer constants were found in fluorescence experiments suggesting the formation of stable protein-ligand complexes. In addition, it was observed that the binding constant between BI2536 and PLK1 increases about 100-fold in presence of the phosphopeptide Cdc25C-p that docks to the polo box domain of the protein and releases the kinase domain. All the determined binding constants are higher for the kinase inhibitors than for their competitor for the active center (ATP) being BI-2536 and Volasertib the inhibitors that showed more affinity for PLK1. Calculated binding free energies confirmed the higher affinity of PLK1 for BI-2536 and Volasertib than for ATP. The higher affinity of the inhibitors to PLK1 compared to ATP was mainly attributed to stronger van der Waals interactions. Results may help with the challenge of designing and developing new kinase inhibitors more effective in clinical cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available